Kymera Therapeutics (KYMR) to Release Earnings on Thursday

Kymera Therapeutics (NASDAQ:KYMR) is projected to release its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Kymera Therapeutics to post earnings of ($0.78) per share for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 9:30 AM ET.

Kymera Therapeutics Price Performance

KYMR opened at $85.11 on Thursday. The business has a 50 day simple moving average of $77.77 and a two-hundred day simple moving average of $63.04. The firm has a market capitalization of $6.12 billion, a price-to-earnings ratio of -23.71 and a beta of 2.21. Kymera Therapeutics has a one year low of $19.44 and a one year high of $103.00.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Stifel Nicolaus set a $114.00 target price on Kymera Therapeutics in a report on Monday, December 8th. Mizuho raised their target price on shares of Kymera Therapeutics from $81.00 to $120.00 and gave the stock an “outperform” rating in a research report on Thursday, December 11th. Bank of America boosted their price target on shares of Kymera Therapeutics from $71.00 to $112.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. BTIG Research restated a “buy” rating and issued a $138.00 price objective on shares of Kymera Therapeutics in a report on Tuesday, February 3rd. Finally, JPMorgan Chase & Co. lifted their price objective on Kymera Therapeutics from $70.00 to $125.00 and gave the company an “overweight” rating in a research report on Wednesday, December 10th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Kymera Therapeutics presently has a consensus rating of “Buy” and an average price target of $117.00.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, Director Bros. Advisors Lp Baker bought 2,005,813 shares of the stock in a transaction dated Thursday, December 11th. The stock was purchased at an average cost of $86.00 per share, for a total transaction of $172,499,918.00. Following the completion of the acquisition, the director owned 7,955,916 shares of the company’s stock, valued at approximately $684,208,776. This trade represents a 33.71% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Nello Mainolfi sold 100,000 shares of the company’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $89.17, for a total value of $8,917,000.00. Following the completion of the sale, the chief executive officer owned 660,482 shares in the company, valued at $58,895,179.94. The trade was a 13.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 420,895 shares of company stock valued at $37,778,351. 16.01% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Kymera Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of KYMR. Price T Rowe Associates Inc. MD grew its position in Kymera Therapeutics by 20.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock valued at $479,258,000 after purchasing an additional 1,061,957 shares during the last quarter. Commodore Capital LP bought a new position in shares of Kymera Therapeutics in the second quarter worth approximately $32,730,000. Alyeska Investment Group L.P. grew its holdings in shares of Kymera Therapeutics by 1,130.2% during the third quarter. Alyeska Investment Group L.P. now owns 615,091 shares of the company’s stock valued at $34,814,000 after buying an additional 565,091 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Kymera Therapeutics by 121.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock valued at $24,535,000 after buying an additional 491,737 shares during the last quarter. Finally, Millennium Management LLC increased its position in shares of Kymera Therapeutics by 340.4% during the first quarter. Millennium Management LLC now owns 510,480 shares of the company’s stock valued at $13,972,000 after acquiring an additional 394,562 shares in the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.